RxDoctor Payments Data

Nidia Miedema, MD

Family Medicine · Muskegon, MINPI 1841306065

Payments from drug & device makers

$1,170in general payments, 2019–2025

Across 36 payments — averaging $32.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$337
  • Amgen$187
  • AbbVie$88
  • Novo Nordisk$86
  • Johnson & Johnson$85
  • Lilly USA, LLC$82
  • plus $305 from 9 others

What the payments were for

  • Food & beverage$1,170100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,170 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$599
Medicare patients
22
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide70$82,228
OxycontinOxycodone Hcl31$34,679
JardianceEmpagliflozin27$31,086
EliquisApixaban17$18,955
XareltoRivaroxaban25$17,539
Advair HfaFluticasone Propion/Salmeterol32$16,636
OzempicSemaglutide18$16,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,145
Icosapent Ethyl15$9,690
Breo ElliptaFluticasone/Vilanterol14$5,522
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen210$4,226
Albuterol Sulfate HfaAlbuterol Sulfate92$3,001
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,956
Methadone Hcl61$2,078
Atorvastatin Calcium215$1,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$82$82,22870 claims
Boehringer IngelheimJardiance$25$31,08627 claims
PfizerEliquis$25$18,95517 claims
Johnson & JohnsonXarelto$85$17,53925 claims
Novo NordiskOzempic$86$16,44818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Muskegon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →